Abstract 363P
Background
Lung cancer with family history have been increasing gradually of late years in East Asian, especially those presenting as pulmonary ground-glass nodules (GGNs). The genome predisposition of GGNs with lung cancer family history remains baffling.
Methods
This prospective study (NCT04220268) enrolled patients with pulmonary pre-invasive or invasive adenocarcinoma, which presenting as GGNs in computer tomography (CT) scans. We collected blood and tumor samples from 59 patients with GGNs and first-degree relative family history of lung cancer (FHLC) to investigated germline and somatic mutations by whole exome sequencing (WES). Pre-invasive neoplasia causal variants were detected by quality, classification, minor allele frequency (MAF), functional prediction, and family segregation filter. Validation was conducted in an external cohort of 669 healthy participants without cancer, and in 126 nonoverlapping susceptibility loci for lung carcinogenesis identified by recent genome-wide association studies (GWAS).
Results
Eighty-five single nucleotide variants (SNVs) and 11 frameshifts were detected, which were rare, predicted as damaging, and presented in more than two families. Fifteen of them had been reported that were associated with high risk of lung cancer or deleterious function. The MAF of them were lower than 0.01 in a local health Asian cohort and human exome databases. Three of them were validated in 126 susceptibility loci for lung carcinogenesis. The number of the rare, damaging and repeatedly germline mutations in non-smoking patients were significantly higher than those in smoking patients (2436 vs 593, p<0.05). The number of these germline mutation showed no significant difference between the patients with pure GGNs and mixed GGNs (1298 vs 1333, p>0.05).
Conclusions
Patients with GGNs and FHLC may have inheritable carcinogenesis mutations. These variants may potentially contribute to the risk of pulmonary pre-invasive adenocarcinoma susceptibility in Chinese population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine (Grant No. 2017B030314120), National Natural Science Foundation of China (Grant No. 81673031&No. 81872510), High-level Hospital Construction Project (DFJH201801), Guangdong Provincial People's Hospital Young Talent Project (No. GDPPHYTP201902).
Disclosure
R-R. Chen, Z-X. Tai, H-X. Lin: Full/Part-time employment: GenePlus-Beijing Institute, Beijing, China. All other authors have declared no conflicts of interest.
Resources from the same session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session
174P - A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study
Presenter: Wenwen Zhang
Session: e-Poster Display Session
175P - A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC)
Presenter: Yanhong Gu
Session: e-Poster Display Session
177P - Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC)
Presenter: Hui-Chuan Sun
Session: e-Poster Display Session
178P - Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis
Presenter: Jaekyung Cheon
Session: e-Poster Display Session
179P - Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy
Presenter: Yue Han
Session: e-Poster Display Session
180P - Real-world (RW) treatment (tx) patterns and outcomes in patients (pts) from Taiwan and Singapore with intermediate and advanced hepatocellular carcinoma (HCC)
Presenter: Su Pin Choo
Session: e-Poster Display Session
181P - Evaluation of first-line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta-analysis
Presenter: Weihua Zhi
Session: e-Poster Display Session
182P - Lenvatinib (LEN) plus anti-PD-1 antibodies vs LEN alone for advanced hepatocellular carcinoma (HCC): A real-world study
Presenter: Qi Li
Session: e-Poster Display Session